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Abstract
Background: The purinergic receptor P2x7 is expressed on myeloid cells as well as on CNS glial
cells, and P2x7 activation has been shown to increase both glial and T-cell activation. These
properties suggest a role in the development of autoimmune disease including multiple sclerosis.
Methods: The animal model of MS, experimental autoimmune encephalomyelitis (EAE) using
myelin oligodendrocyte glycoprotein (MOG) peptide residues 35–55 was induced in wildtype
C57BL6 mice and in P2x7 deficient mice ('P2x7 mice') that were backcrossed to C57BL6 mice.
Disease progression was monitored by appearance of clinical signs, immunocytochemical staining
to assess brain inflammation and neuronal damage, and by measurement of Tcell cytokine
production.
Results: The incidence of EAE disease in P2x7 mice was reduced 4-fold compared to the wildtype
mice; however the P2x7 mice that became ill had similar days of onset and clinical scores as the
wildtype mice. Splenic T-cells isolated from P2x7 null mice produced greater IFNγ and IL-17 (from
3 to 12 fold greater levels) than wildtype cells, however cytokine production from P2x7 derived
cells was not increased by a selective P2x7 agonist as was cytokine production from wildtype cells.
Although infiltrating cells were detected in brains of both the P2x7 and wildtype mice, astroglial
activation and axonal damage was reduced versus wildtype mice, and the distribution of astroglial
activation was markedly distinct in the two strains. In contrast, microglial activation was similar in
the two strains.
Conclusion:  P2x7 deficiency resulted in compensatory changes leading to increased T-cell
cytokine production, and activated T-cells were detected in the brains of P2x7 null mice with no
clinical signs. However, the greatly reduced incidence of disease suggests that an initiating event is
absent in these mice, and points to a role for astroglial P2x7 in development of EAE disease.
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Background
Multiple sclerosis (MS) is an autoimmune demyelinating
disease in which activated T-lymphocytes infiltrate the
CNS, secrete pro-inflammatory substances which activate
parenchymal glial cells, and ultimately lead to oli-
godendrocyte and neuronal damage. During this process,
cell damage or death can lead to increased levels of extra-
cellular ATP, which can act upon purinoceptors on neu-
rons and glia. The P2X7 receptor is a ligand-gated ion
channel predominantly expressed on immune cells of the
periphery (mainly macrophages) and CNS (microglia),
but has also been detected in astrocytes [1-3], oli-
godendrocytes [4,5] and neurons [6,7]. P2X7 is activated
by high concentrations (in the 100 μM range) of ATP and
prolonged agonist activation leads to the formation of a
large cytolytic pore in the cell membrane. Activation of
P2X7 causes depolarization, leading to an increase in K+
efflux, and eventual activation of the inflammasome (a
large multiprotein complex implicated in caspase-1 and
caspase-5 activation [8]. As a consequence, caspase-1 is
activated leading to a rapid maturation and release of the
potent pro-inflammatory cytokine IL-1β, a key initiator of
the inflammatory cascade [9-11]. Activation of P2x7 in
brain can also increase glial calcium and sodium influx
[12], increase reactive oxygen and nitrogen species
[13,1,14]; modulate glial efflux of glutamate and ATP
[2,3,15] and has been associated with neuronal damage
[16,17].
P2x7 activation plays a role in the regulation of lym-
phocyte activation. Activation of P2x7 by ligands includ-
ing ATP, by transfer of ribosyl groups from extracellular
NAD+ to P2x7 [18,19], or by synthetic ligands including
2',3'-(benzoyl-4-benzoyl)-ATP (BzATP) induces pore for-
mation, Ca2+ influx, annexin V staining, and cell death in
T-cells [20], natural killer cells (NKTs, [21], and regulatory
T-cells (Tregs, [22]). Interestingly, in some cases it was the
unprimed, naïve cells that were more sensitive to P2x7
dependent cell death [20,21], while the activated cells
were resistant and instead were further activated by P2x7.
Thus, P2x7 activation can result in either reduced or exac-
erbated lymphocyte responses [23].
The above findings suggests that increases in extracellular
levels of ATP or NAD+ which could occur during MS
could contribute to inflammatory damage by activating
P2x7, and studies using P2x7 antagonists or deficient mice
support this idea. In macrophages, it was shown that
while responses to LPS (an increase in cyclooxygenase 2
expression and pro-IL1β production) was similar in
wildtype (WT) and P2x7 null mice, the increased response
to ATP (increased externalization and processing of pre-
IL1β to mature IL1β; and subsequent increase in IL-6
expression) was absent in the null mice [24]. In vivo, pro-
longed activation of P2x7 (accomplished by infusion of
the potent and selective ligand BzATP) resulted in tissue
damage, gliosis, and axonal damage reminiscent of EAE;
while treatment of EAE mice with P2x7 antagonists amel-
iorated clinical symptoms and reduced demyelination [4].
However, characterization of EAE disease in P2x7 null
mice [25] unexpectedly showed more severe disease in the
null mice versus wildtype controls (C57Bl6 mice), associ-
ated with a greater number of lesions in brain, increased
lymphocyte proliferation and reduced lymphocyte cell
death, and reduced splenic cell production of pro-inflam-
matory cytokines including IL-6 and IFNγ. In a related
study [26], the authors reported that axonal damage in
P2x7 null mice was increased compared to that in the WT
mice. These results led to the conclusion that P2x7 is
important for regulating lymphocyte numbers and sub-
types, and therefore critical to the development of EAE
disease.
In the current study, we have re-evaluated the conse-
quences of P2x7 deficiency on the progression of MOG
peptide induced EAE disease using a distinct strain of
P2x7 null mice [27-29]. In contrast to the mice used for
previous EAE studies, in which deficiency was achieved by
homologous recombination of the neomycin gene into
exon 5 [24], in the current studies P2x7 deficiency was
achieved by neomycin insertion into exon 1 [27]. In these
mice, the conversion of pro-IL-1β to mature, released IL-
1β is absent from activated macrophages, demonstrating
the absence of P2x7 dependent IL-1β production. How-
ever whether other cell types express any P2x7 dependent
responses was not determined. In the current study, we
found that the overall incidence of EAE disease was signif-
icantly reduced in P2x7 null mice compared to controls.
However, cytokine production from splenic T-cells iso-
lated from immunized P2x7 null mice was greater than
that observed from WT cells, suggesting a compensatory
response to P2x7 deficiency. Within the CNS, astroglial
activation was present but reduced in the P2x7 null mice;
and axonal damage less. These results are consistent with
the idea that activation of P2x7 in parenchymal astrocytes
cells is a main contributor to disease pathogenesis, and
therefore treatment with CNS-penetrant P2x7 antagonists
should be considered as a therapeutic option in MS.
Methods
Mice
P2x7 deficient mice were described previously and were
obtained from Glaxo-Smith-Kline (Harlow, Essex) [27].
These mice have been backcrossed onto a C57BL6 back-
ground. As controls, we used female C57BL/6 mice, aged
6–8 weeks from Charles River Breeding (Cambridge, MA).
Mice were maintained in a controlled 12:12 hr light/dark
environment and provided food ad libitum. All experi-
ments were approved by the local animal care committee.Journal of Neuroinflammation 2008, 5:33 http://www.jneuroinflammation.com/content/5/1/33
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Induction of EAE
EAE was actively induced in C57BL/6 and P2x7 null mice
using synthetic myelin oligodendrocyte glycoprotein pep-
tide 35–55 (MOG35–55) as described [30]. The MOG35–55
peptide (MEVGWYRSPFSRVVHLYRNGK) was obtained
from Anaspec (San Jose, CA), and purified to >98% purity
by reverse phase HPLC analysis. Mice were injected subcu-
taneously (two 100 μL injections into adjacent areas in
one hind limb) with an emulsion of 300 μg MOG35–55 dis-
solved in 100 μL PBS, mixed with 100 μL CFA containing
500 μg of Mycobacterium tuberculosis (Difco, Detroit,
MI). Immediately after MOG35–55 injection, the animals
received an i.p. injection of pertussis toxin (PT, 200 ng in
200 μL PBS). Two days later the mice received a second PT
injection, and 1 week later they received a booster injec-
tion of MOG35–55. Clinical signs were scored on a 5 point
scale: grade 0, no clinical signs; 1, limp tail and/or
impaired righting; 2; paresis of one hind limb; 3; paresis
of two hind limbs; 4; moribund; 5, death. Scoring was
done at the same time each day by a blinded investigator.
T-cell isolation and cytokine measurements
Splenocytes were isolated from MOG35–55  immunized
EAE mice at 4 days or 21 days after the booster MOG injec-
tion. After lysis of red blood cells, splenocytes were plated
into 24 well plates at a density of 2 × 105cells per well in
400 μl RPMI media, and incubated with immunogen (0
or 25 μg/ml MOG 35–55 peptide). After 1 day, aliquots of
the media were assayed for levels of IL-17 or IFNγ by
ELISA following recommended procedures (Quantikine
M, R&D Systems, Minneapolis, MN). Each sample was
assayed at least in triplicate, calculation of ng/ml cytokine
determined from standard curves, and the increase due to
the presence of MOG peptide was determined. A semi-
quantitative analysis of 64 inflammatory molecules pro-
duced by activated splenocytes was carried out using the
mouse cytokine antibody array III (RayBiotech) according
to the manufacturer's protocols.
Analysis for infiltrating cells
Mouse brains were perfused with saline and post fixed in
4% paraformaldehyde overnight. Dehydration of hemi-
spheres was through a series of 80%, 95% ethanol one
hour each followed by 100% ethanol overnight. Two
100% xylene washes were done for 1 hour each and then
1 hour in 60°C Paraplast Plus (Tyco/Healthcare, Mans-
field, MA). After a change of Paraplast Plus, tissue was
placed in a 60° vacuum oven for 2 hours prior to placing
in molds to cool and solidify. Tissue was cut 8 μm thick.
Sagital sections (8 or 10 μM) were cut beginning from
midline, and mounted. Sections were deparaffinized by
drying overnight on superfrost plus slides (Fisher), heat-
ing at 56°C for 2 hr, and then washing through mixed
xylenes, 100% ethanol, 95% ethanol, ddH2O, and then
stained with hematoxylin and eosin. Four serial sections
from each animal were analyzed for the number of infil-
trating cells present in the region extending from the
olfactory bulb to the dorsal third ventricle using Zeiss
Axiovision 4.3 software. Black and white images of all
stained sections were obtained using the same exposure
time with a 10× objective. Specific fields containing small
round hematoxylinophyllic nuclei were defined, and con-
trast adjusted so as to not count larger round cells presum-
ably oligodendrocytes. The software automatically counts
the number of independent objects (nuclei) within the
field of interest; and data is presented as number of cells
per mm2.
Immunohistochemisry was used to detect T-cells. For this,
frozen sections were stained using an anti-CD8 antibody
(Pharmingen, Mouse IgG, 1:500). Sections were incu-
bated in 3% BSA in PBS plus antibody overnight at 4°C,
washed, and then developed with a secondary antibody
labeled with FITC.
Immunohistochemistry
Sagittal mouse brain sections mounted on slides and
deparaffinized as above, Antigen retrieval was accom-
plished by boiling for 10 minutes in 10 mM NaCitrate pH
6.0 and allowing slides to gradually cool to room temper-
ature. Slides were then washed three times for 2 min. with
ddH2O, then washed 5 min with PBS and blocked with
5% normal donkey serum in PBS at room temperature for
30 min. Primary antibodies were diluted in 1% normal
donkey serum: mouse monoclonal antibody anti-SMI-32
1:200 (Sternberger Monoclonals Inc., Lutherville, MD);
rabbit anti-MBP 1:300 (Zymed Laboratories, San Fran-
cisco, CA); rat anti-human GFAP monoclonal antibody
B2.210 1:300 (a gift of V. Lee), and sections were incu-
bated 4°C overnight. Sections were washed 3 times with
PBS. Secondary antibodies (Jackson ImmunoResearch
Inc., West Grove, PA) were donkey anti-rabbit RRX conju-
gated, donkey anti-rat FITC conjugated, or mouse on
mouse kit conjugated with FITC (Vector Labs, Burlin-
game, CA). All secondary antibodies were incubated for 1
hour at 37°C and diluted 1:200 in PBS with 1% normal
donkey serum. Slides were washed 3 times 5 minutes with
PBS and post-fixed in 3.7% formaldehyde in PBS for 20
min. DAPI staining of nuclei, 400 ng/ml in PBS, was done
after one wash with PBS and followed with 3 PBS washes.
Vectashield mounting fluid (Vector Laboratories Inc., Bur-
lingame, CA) was used. Images were obtained on a Zeiss
Axioplan2 fluorescence microscope equipped with an Axi-
ocam MRm digital camera and Axiovision 4.3 imaging
software. For each analysis, at least 3 mice from each
group were included, and 3–4 serial sections were ana-
lyzed from each mouse.
To detect activated microglia, free floating cryosections (8
μm) were immunostained using the F4-80 clone (Chemi-Journal of Neuroinflammation 2008, 5:33 http://www.jneuroinflammation.com/content/5/1/33
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con, rat IgG 1:200). Briefly, sections were rinsed in PBS
and endogenous peroxidase quenched by incubation in
methanol:hydrogen peroxide before blocking in 3% BSA
in PBS. After overnight incubation with F4-80 at 4°C, sec-
tions were processed for biotin-streptoavidin-peroxidase
staining as recommended by the manufacturer (Vector
Labs). Sections were developed using diaminobenzidine
and hydrogen peroxide.
Data analysis
The data from 3 separate EAE studies of P2x7 null mice
and 2 separate studies done in WT mice was combined
and analyzed. Data is presented as the mean ± sem, and
differences between group averages were determined by
unpaired, nonparametric T-test with P < 0.05 considered
significant. Data in figures 2 and 3 are presented as mean
± sd. The effects of BzATP treatment on cytokine produc-
tion were analyzed by 1-way ANOVA and Bonferroni's
multiple comparison post hoc test.
Results
P2x7 deficiency suppresses clinical symptoms in EAE
The clinical course of EAE disease was monitored in P2x7
null and wildtype (WT) C57BL/6 mice (Figure 1). In data
obtained from 3 separate studies (Table 1), the overall
incidence of disease (Figure 1A) was significantly
decreased (to 7/38 or 18%) in P2x7 null mice compared
to controls (15/24 or 63%); although the average day of
onset for those mice that became ill was similar to the WT
mice. Comparison of the clinical scores for all mice (ill
and non-ill, Figure 1B) shows that the average scores were
significantly lower in the P2x7 null group compared to
WT group; however the development of clinical disease
and maximum scores of the mice that became ill in each
group were similar (Figure 1C). These data suggest that
absence of P2x7 significantly reduces the incidence of
EAE, but those mice that become ill have a similar disease
course do the WT mice.
Effects of P2x7 deficiency on T-cell activation
Antigen restimulation of cytokine production was meas-
ured in splenic T-cells isolated from EAE immunized mice
4 days after the booster immunization (Figure 2). We
noted that the spleens from P2x7 null mice were larger
than those from WT mice, and the total yield of spleno-
cytes about twice as great (not shown), consistent with the
report that P2x7 null splenocytes proliferated more than
the WT cells [25]. T-cells from the WT mice (Figure 2A)
produced basal levels of IFNγ (39.9 ng/ml) which were
increased about 4-fold by MOG peptide (150 ng/ml).
Cells from P2x7 null mice (Figure 2B) produced similar
basal levels of IFNγ (54 ng/ml) which were increased to a
greater extent (about 12-fold) by MOG than in the WT
cells. WT cells also produced basal levels of IL-17 (18 ng/
ml, Figure 2C) which were increased about 2-fold by
MOG; whereas P2x7 null cells (Figure 2D) basally pro-
duced about 11 ng/ml IL-17 which was increased almost
25-fold by MOG. These results demonstrate that P2x7 null
T-cells are efficiently primed and respond to antigen to the
same or greater extent than do WT-derived cells.
We compared the effects of the selective P2x7 agonist
BzATP on splenocyte responses to ex vivo restimulation
with MOG peptide. In WT cells, co-incubation with 100
μM BzATP significantly increased both IFNγ and IL-17
production about 2-fold (Figure 2A, C). In contrast,
BzATP did not increase cytokine production from P2x7
null cells (Figure 2B, D). This suggests that despite a com-
pensatory effect leading to increased T-cell activation, the
lack of a functional P2x7 limits further potentiation by
selective ligands.
The increased response of P2x7 null splenocytes was not
limited to IL-17 and IFNγ, since a membrane-based ELISA
assay showed that P2x7 null derived splenocytes pro-
duced increased levels (50% or greater) of several other
inflammatory factors including IL-12p40 subunit, MCP1,
CXCL16, IL-3 and it's receptor IL-3Rb, L-selectin, and
eotaxin (data not shown).
Effects of P2x7 deficiency on brain histopathology
Histological analysis revealed the presence of infiltrating
cells throughout the brain of P2x7 null mice that did not
develop any clinical signs, including cells located in small
perivascular lesions in the cerebellum (Figure 3A, B) and
beneath the corpus callosum and lining the lateral ventri-
cles (Figure 3C, D). These cells represent infiltrating lym-
phocytes as previously shown [30]. A quantitative
assessment of the latter showed a similar, if not greater
number of infiltrating cells in P2x7 brains as in the WT
brains (Figure 3E). Immunocytochemical staining of cere-
bellum revealed the presence of CD8 positive Tcells in the
white matter and granule layers of both WT (Figure 4A, C)
and P2x7 (Figure 4B, D) mice.
Astrocyte activation, assessed by staining for GFAP was
found throughout the brains of WT mice at the peak of
clinical disease (Figure 5). In contrast, while some GFAP
staining was detected in the brains of P2x7 null mice, it
was reduced compared to WT mice in many regions
including the somatosensory region of cortex projecting
to hindlimb and trunk areas (Figure 5A, B), corpus callo-
sum, and underlying thalamic area (Figure 5C, D). In the
cerebellum of WT EAE mice, GFAP staining was detected
in the white matter as well as in Bergman radial glial fibers
(Figure 5E), while in P2x7 null mice robust GFAP staining
was only observed in cerebellar white matter (Figure 5F).
These data suggest that parenchymal astrocyte activation
is reduced in the knockout mice compared to WT mice.Journal of Neuroinflammation 2008, 5:33 http://www.jneuroinflammation.com/content/5/1/33
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Effect of P2x7 deficiency on the development of clinical signs of EAE Figure 1
Effect of P2x7 deficiency on the development of clinical signs of EAE. P2x7 null and wildtype C57BL6 mice were 
immunized to develop EAE using MOG35–55 peptide, and clinical scores monitored approximately daily. Day 0 is defined as the 
day of the MOG peptide booster immunization. The data from 3 separate studies using P2x7 null mice (n = 38 total) and 2 sep-
arate studies using WT mice (n = 24 total) are combined. Data in (A) shows average incidence of disease (defined by at least 2 
consecutive days with a score of 1.0 or greater). Data in (B) shows average clinical scores (mean ± se) for all mice. Data in (C) 
show average clinical scores (mean ± se) for only those mice that became ill (7/38 in the P2x7 null group; and 15/24 in the WT 
group).Journal of Neuroinflammation 2008, 5:33 http://www.jneuroinflammation.com/content/5/1/33
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In contrast to astrocyte activation, immunostaining using
monoclonal antibody F4/80, a marker of activated micro-
glia and macrophages, revealed similar levels and patterns
of microglia activation in WT and P2x7 null mice (Figure
6). In the cerebellum, strongly stained cells with typical
microglial morphology were observed in white matter of
WT and P2x7 null mice (Figure 6A, D), and diffuse stain-
ing in the molecular layer (Figure 6B, E). Robust micro-
glial activation was also observed in the corpus callosum
of both strains (Figure 6C, F). In contrast to GFAP, we did
not observe strong F4/80 staining any any cortical areas
(not shown). These results suggest that microglial activa-
tion is similar in P2x7 null and WT mice at the time point
examined.
Immunostaining for the presence of non-phosphorylated
neurofilament protein revealed axonal damage in the cer-
ebellar molecular layer in WT mice (Figure 7A), emanat-
ing outwards from the strongly stained Purkinje cell layer
(Figure 7C), and having a distinct localization from that
of the increased GFAP staining (Figure 7E). In contrast,
axonal damage in the molecular layer was minimal in the
the P2x7 null mice (Figure 7B, D), as was staining for acti-
vated astrocytes (Figure 7F).
Discussion
Our data demonstrate that P2x7 deficiency significantly
reduces the incidence of EAE disease compared to control
C57BL6 mice; however the mice which developed disease
Effect of P2x7 deficiency on splenic T-cell cytokine production Figure 2
Effect of P2x7 deficiency on splenic T-cell cytokine production. P2x7 and wildtype C57BL6 mice were immunized to 
develop EAE as above, and at 4 days after the booster immunization, splenic T-cells isolated and cultured in the presence (filled 
bars) or absence (open bars) of 20 μg/ml MOG peptide, and either 0, 50, or 100 μM BzATP. After 24 hr, levels of IFNγ and IL-
17 in the culture media were determined by specific ELISA. Cytokine production is shown for WT (A, C) and P2x7 null (B, D) 
cells. Values are the mean ± sd of n = 3 independent samples. *, P < .001 versus no BzATP.Journal of Neuroinflammation 2008, 5:33 http://www.jneuroinflammation.com/content/5/1/33
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(7 of 38 total) showed a similar day of onset and reached
similar disease severity as the ones that became ill in the
control group. This suggests that the presence of P2x7 is
necessary for efficient initiation of disease, but that dis-
ease can occur, albeit at a reduced level, in the absence of
P2x7. The nature of the initiating event (or events) is not
known, but our findings suggest that it does not involve T-
cell activation or their ability to infiltrate into the CNS;
but instead reflects a difference in inflammatory responses
of parenchymal astrocytes.
Despite significantly reduced disease incidence, we found
that cytokine production from splenocytes isolated from
P2x7 null mice that did not show any clinical signs was as
high as or greater than that measured in splenocytes
obtained from C57BL/6 mice that exhibited clinical signs.
While basal production of IFNγ and IL-17 was similar, res-
timulation with MOG peptide led to significantly greater
cytokine production in the P2x7 null cells compared to
controls. This finding suggests that P2x7 deficiency can
lead to increased T-cell activation, although whether it is
an effect on the Tcells or other cells present (e.g. dendritic
cells) is not known. A recent study reported that while
Histological staining for infiltrating cells in P2x7 and WT mice Figure 3
Histological staining for infiltrating cells in P2x7 and WT mice. Serial sections were prepared from EAE immunized 
P2x7 null and WT mice at day 21 after immunization. At this time, the 3 WT mice had clinical scores of 2.0; and the 3 P2x7 null 
mice had no clinical signs. Sections were stained with H&E to detect the presence of infiltrating cells. Representative sections 
from the cerebellum show the presence of perivascular infiltrating cells (arrows) in the cerebellar white matter of both P2x7 
(A) and WT (B) brains. Sections taken from near the IVth ventricle show the presence of infiltrating cells (arrows) beneath the 
corpus callosum and lining the ventricle in both P2x7 (C) and WT (D) brains. (E) Quantitation of the average total number of 
infiltrating cells (mean ± sd) measured in 4 serial sections for P2x7 and WT mice (n = 3 mice each).
Table 1: Clinical symptoms in P2x7 null and C57Bl6 wildtype 
mice
Study Incidence Mean Onset Maximal
 Score All
Maximal
 Score ill
P2x7 null
Expt 1 4/18 (22%) 10.8 ± 1.3 0.4 ± 0.2 2.0 ± 0.0
Expt 2 0/8 (0%) nd 0 0
Expt 3 3/12 (25%) 14.3 ± 2.3 0.4 ± 0.3 1.3 ± 0.2
Total 7/38 (18%) 12.3 ± 1.2 0.3 ± 0.1 1.7 ± 0.2
C57BL/6
Expt 1 7/12 (64%) 12.7 ± 0.6 1.2 ± 0.3 1.9 ± 0.1
Expt 2 8/12 (67%) 12.7 ± 1.0 1.4 ± 0.3 2.1 ± 0.1
Total 15/24 (63%) 12.7 ± 0.6 1.2 ± 0.7 1.9 ± 0.1Journal of Neuroinflammation 2008, 5:33 http://www.jneuroinflammation.com/content/5/1/33
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activation of P2x7 increased cytokine production from
activated Natural Killer T-cells (NKTs), it also increased
apoptosis of naïve NKT cells [21]. Therefore, increased T-
cell activation could be due to reduced death of regulatory
NKT cells. Our data also demonstrates that, in contrast to
WT cells, the P2x7 null cells do not increase cytokine pro-
duction in response to BzATP. It is therefore possible that
within the context of an inflammatory milieu as exists in
EAE, increased extracellular levels of ATP (or of other ago-
nists which can activate P2x7) can promote cytokine pro-
duction from WT cells but not from P2x7 deficient cells.
Despite the increased ability of P2x7 null T-cells to pro-
duce cytokines, and the presence of lymphocytes in the
brains of P2x7 null mice, the majority of the mice showed
no clinical signs, suggesting that parenchymal production
of inflammatory factors is attenuated. We used GFAP
staining as an index of astrocyte activation, and observed
that while there is extensive astrocyte activation though
out the brains of C57BL6 mice that showed clinical signs,
there was limited GFAP staining in the P2x7 null mice. In
particular, we noticed that in the cerebellum of the control
mice, GFAP staining was present in the white matter area
as well as in processes of radial glial cells extending
through the molecular layer. In contrast, GFAP staining in
the P2x7 null mice was mainly observed in the cerebellar
white matter. These observations indicate that astroglial
CD8 T-cells are expressed in WT and P2x7 cerebellum Figure 4
CD8 T-cells are expressed in WT and P2x7 cerebellum. Serial sections as prepared in Figure 3 were stained with anti-
body to CD8 to detect the presence of T-cells. Representative images from one mouse in each group show the presence of 
CD8 cells in both the granule layer ('GL', Panels A and B) and white matter ('WM', Panels C and D) of WT and P2x7 animals.Journal of Neuroinflammation 2008, 5:33 http://www.jneuroinflammation.com/content/5/1/33
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GFAP expression is reduced in P2x7 brain Figure 5
GFAP expression is reduced in P2x7 brain. Serial sections were prepared from EAE immunized P2x7 null and WT mice 
at day 21 after immunization. At this time, the 3 WT mice all had clinical signs of 2.0; and the 3 P2x7 null mice had no clinical 
signs. Sections were stained with antibody to GFAP to detect activated astrocytes. Representative images show robust GFAP 
staining in WT frontal cortex (A) and thalamus (C), but not in corresponding areas of P2x7 null cortex (B) or thalamus (D). 
Significant staining for GFAP was found throughout the cerebellar grey and white matter in the WT mice (E) but was restricted 
to white matter (W) in P2x7 mice (F). S1HL, somatosensory hindlimb region; S1Trl, somatosensory trunk region; LV, lateral 
ventricle; HC, hippocampus; Th, laterodorsal thalamic nuclei; WM, white matter; ML, molecular layer; PL, Purkinje cell layer; 
GL, granule cell layer. Size bars are 200 μm.Journal of Neuroinflammation 2008, 5:33 http://www.jneuroinflammation.com/content/5/1/33
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Microglial activation is similar in P2x7 and WT brain Figure 6
Microglial activation is similar in P2x7 and WT brain. Serial sections from WT (A, B, C) and P2x7 null (E, F, G) mice 
as described in Figure 5 were stained with monoclonal antibody F4/80 to detect activated microglia and macrophages. Repre-
sentative images from one mouse in each group show the presence of cells with characteristic morphology of microglia in cer-
ebellar white matter ('WM', panels A, D) and corpus callosum ('CC', panels C, F); and diffuse staining in cerebellar granule 
layer ('GL', panels B, E).Journal of Neuroinflammation 2008, 5:33 http://www.jneuroinflammation.com/content/5/1/33
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Axonal damage is reduced in P2x7 brain Figure 7
Axonal damage is reduced in P2x7 brain. Serial sections were prepared from EAE immunized P2x7 null and WT mice at 
day 21 after immunization. At this time, the 3 WT mice all had clinical signs of 2.0; and the 3 P2x7 null mice had no clinical 
signs. Sections were stained with antibody SMI32 (for non phosphorylated neurofilament proteins, A-D) or to GFAP (E, F). 
Representative images show significant SMI32 staining in an area of the cerebellum from WT (A, C) mice, but little staining in a 
comparable area from P2x7 null (B, D) mice. Size bars are 100 μM (A, B) and 50 μm (C-F). GFAP staining (E, F) illustrates the 
differences in localization for GFAP and SMI32 staining. Asterisks and arrows are placed to indicate same location in images. 
ML, molecular layer; PL, Purkinje cell layer; GL, granule cell layer.Journal of Neuroinflammation 2008, 5:33 http://www.jneuroinflammation.com/content/5/1/33
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activation does occur in the P2x7 null mice but in a
restricted manner compared to controls.
In contrast to a clear differential degree of astrocyte activa-
tion, staining using monoclonal antibody F4/80 did not
reveal significant differences in microglial activation
between WT and the P2x7 null mice, suggesting an impor-
tant role for astroglial P2x7 during EAE disease progres-
sion. There are several ways by which lack of P2x7 from
astrocytes, could provide benefit during EAE that may not
be shared with microglial cells. Astrocytes, but not micro-
glia, have been shown to release purines following P2x7
activation [31], which could contribute to ongoing
inflammation. In astrocytes, P2x7 activation induces
ERK1/2 phosphorylation [32] and activation of the PI3/
Akt signaling system [33], both which can contribute to
increase inflammatory responses; but this has not been
demonstrated to occur in microglial cells. An important
function of astrocytes is to remove excessive glutamate
from the extracellular environment, which could other-
wise contribute to neuronal damage. A recent study [34]
demonstrates that activation of P2x7 receptors on astro-
cytes reduces glutamate uptake as well as glutamine syn-
thetase. Similarly, it has been shown that P2x7 activation
can induce glutamate release from astrocytes [35]. In a
recent study [36], it was shown that astrocytes express a
greater repertoire and higher levels of excitatory amino
acid transporters than do microglial cells; and astrocytes
but not microglia prevented excito-neurotoxicity due to
glutamate. Astrocytes, but not microglia, have been
shown to express the glutamate transporter GLT-1, as well
as high levels of glutamate metabolizing enzymes in post
mortem MS brain samples [37]. Together these findings
suggest that astroglial regulation of extracellular gluta-
mate levels may be of greater importance during neurode-
generative diseases, and therefore perturbation of
astrocyte glutamate uptake by activation of P2x7 could
have more drastic consequences.
The question arises as to why in a previous study P2x7
deficiency exacerbated EAE disease [25]. As noted above,
the mice used in that study were generated with a strategy
in which the recombination event targeted P2x7 exon V,
while in the current study the neomycin cassette was
inserted into exon I. This raises the possibility that an
alternate form of P2x7 is expressed thus leading to a dis-
tinct phenotype. It has been reported that a variant of
P2x7 is expressed in certain cell types [38,6]. If so, an alter-
nate form of P2x7 in T-cells could contribute to increased
cytokine production. This is also consistent with the fact
that the P2x7 gene that was targeted for knockout in the
founding 129 mouse line was the 415P allele, which is
known to be more active than the 415L present in the
C57Bl6 background [39]. While identification of possible
alternative P2x7 transcripts remains to be determined,
these studies confirm an important role for this receptor
during the course of EAE, and by inference, MS disease.
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